Both CDKN2A gene products, p14 and p16, can inhibit angiogenesis in glioma cells by upregulating tissue inhibitor of metalloproteinase‐3 or downregulating vascular endothelial growth factor, respectively [27, 31], indicating that the loss of CDKN2A may promote blood vessel growth in vivo. The gene discussed is VEGFA; the disease is central nervous system cancer.